Supernus Pharmaceuticals (SUPN) Other Gross PP&E Adjustments (2016 - 2025)
Supernus Pharmaceuticals (SUPN) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with -$14.6 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments fell 139.21% to -$14.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$14.6 million, a 139.21% decrease, with the full-year FY2025 number at -$14.6 million, down 139.21% from a year prior.
- Other Gross PP&E Adjustments was -$14.6 million for Q4 2025 at Supernus Pharmaceuticals, down from -$13.5 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $28.0 million in Q1 2021 to a low of -$36.4 million in Q2 2022.
- A 5-year average of -$2.5 million and a median of -$6.9 million in 2024 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 202.33% in 2021, then tumbled 332.67% in 2022.
- Supernus Pharmaceuticals' Other Gross PP&E Adjustments stood at -$28.7 million in 2021, then skyrocketed by 39.11% to -$17.5 million in 2022, then surged by 32.87% to -$11.7 million in 2023, then soared by 48.01% to -$6.1 million in 2024, then tumbled by 139.21% to -$14.6 million in 2025.
- Per Business Quant, the three most recent readings for SUPN's Other Gross PP&E Adjustments are -$14.6 million (Q4 2025), -$13.5 million (Q3 2025), and -$7.8 million (Q2 2025).